Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD1 therapy.

Łukasz GalusMichał MichalakMateusz LorenzRenata Stoińska-SwiniarekDaria Tusień MałeckaAgnieszka GalusTomasz KolendaEwa LeporowskaJacek Mackiewicz

Published in: Cancer (2023)

In our opinion, maintaining the vitamin D level within the normal range during anti-PD-1 immunotherapy in advanced melanoma patients should be a standard procedure allowing the improvement of treatment outcomes.

Keyphrases

end stage renal disease
newly diagnosed
peritoneal dialysis
prognostic factors
skin cancer
smoking cessation